Corrigendum to “Identification through structure-based methods of a bacterial NAD+-dependent DNA ligase inhibitor that avoids known resistance mutations” [Bioorg. Med. Chem. Lett. 24 (2014) 360–366]

From fragments to leads: novel bacterial NAD + -dependent DNA ligase inhibitors

“…4 AstraZeneca reported a series of potent adenosine based inhibitors. 5 There have also been reports of inhibitors from a number of classes including: arylamino acids, 6 tetracyclic indoles, 7 glycosyl ureides and glycosylamines, 8 pyrimidopyrimidines, 9 aminoalkoxypyrimidines, 10 thienopyridines, 11 and anilines. 10a,b In an effort to develop a novel broad spectrum LigA inhibitor, we used previously disclosed structure-activity relationships (SAR) for LigA inhibitors; results from in-house high-throughput screens (HTS), including a high-concentration fragment screen and X-ray crystal structures of LigA with inhibitors bound.…”